You are viewing: Japan Humanized Mouse and Rat Model Market analysis

The Japan Humanized Mouse and Rat Model Market was valued at $12.9 Million in 2025 and projected to reach to $19.7 Million by 2030, representing a compound annual growth rate of 8.8%. Japan's humanized mouse and rat model market is positioned for sustained growth, driven by the country's advanced pharmaceutical infrastructure and increasing demand for sophisticated preclinical testing solutions.

Japan Humanized Mouse and Rat Model Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Japan Humanized Mouse and Rat Model Market Trends and Insights

  • Japan has emerged as a key hub for preclinical research and drug development in Asia Pacific, driven by strong pharmaceutical and biotechnology sectors investing heavily in advanced animal models for disease research and therapeutic validation.
  • The adoption of humanized models in Japan reflects the country's commitment to reducing animal testing while maintaining scientific rigor in drug discovery pipelines. Japan's market growth is underpinned by increasing R&D expenditure, regulatory support for alternative testing methodologies, and collaborations between academic institutions and pharmaceutical companies.
  • Japan's aging population and prevalence of chronic diseases have intensified demand for personalized medicine research, where humanized mouse and rat models play a critical role.
  • Between 2025 and 2030, Japan is expected to see accelerated adoption across oncology, immunology, and infectious disease research segments, positioning the country as a regional leader in translational research capabilities..

Key Market Statistics

  • CAGR (2025-2030) 8.8% CAGR
  • Market Size, 2025 ~USD 12.9 Million
  • Forecast, 2030 ~USD 19.7 Million
  • Country Japan

Japan Humanized Mouse and Rat Model Market Overview

Strong Pharmaceutical Investment :

Japan's robust pharmaceutical and biotechnology sectors are driving significant investments in humanized mouse and rat models for preclinical research and drug development activities.

Asia Pacific Research Hub :

Japan has established itself as a key preclinical research hub in the Asia Pacific region, attracting international collaborations and partnerships for advanced animal model research.

Consistent Growth Trajectory :

The market is expanding at a CAGR of 8.8% from 2025 to 2030, outpacing the global growth rate of 8.2%, indicating accelerating adoption in Japan.

Market Valuation Expansion :

Japan's humanized mouse and rat model market is projected to grow from USD 12.9 million in 2025 to USD 19.7 million by 2030, representing a 52.7% increase over five years.

Japan Humanized Mouse and Rat Model Market Dynamics

  • The market's 8.8% CAGR reflects growing investments by Japanese biotech companies and research institutions in developing more accurate disease models for drug efficacy and safety testing. The expansion is supported by Japan's aging population creating demand for novel therapeutics, coupled with regulatory requirements for comprehensive preclinical data.
  • Strategic partnerships between Japanese pharmaceutical companies and international research organizations are expected to further accelerate market penetration and innovation in humanized animal model technologies through 2030..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Japan's humanized mouse and rat model market is valued at USD 12.9 million in 2025 and will reach USD 19.7 million by 2030, growing at 8.8% CAGR.
    • Japan's strong pharmaceutical and biotechnology sectors are driving demand for advanced preclinical research models to accelerate drug discovery and development.
    • Regulatory support for alternative testing methodologies and ethical research practices in Japan is fostering adoption of humanized animal models.
    • Japan's aging population and focus on personalized medicine are creating sustained demand for humanized models in oncology, immunology, and infectious disease research.

    Humanized Mouse and Rat Model Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS AND CDMOS) (End User)
    Forecast Period 2025–2030
    Growth Rate CAGR of 8.2% from 2025 to 2030
    Largest Segment HUMANIZED MOUSE MODELS (Type)
    Market Size Base Year (Billions) ~USD 0.28 (2025)
    Revenue Forecast (Billions) ~USD 0.41 (2030)
    Segments Covered Type, End User, Application

    Japan Humanized Mouse and Rat Model Market Report Segmentation

    3 segment dimensions are covered across the global market.

    By Type

    • Blt Humanized Mouse Models
    • Cd34 Humanized Mouse Models
    • Cell-Based Humanized Mouse Models
    • Genetic Humanized Mouse Models
    • Humanized Mouse Models
    • Humanized Rat Models
    • Pbmc Humanized Mouse Models

    By End User

    • Academic & Research Institutes
    • Academic And Research Institutes
    • Contract Research Organizations And Contract Development And Manufacturing Organizations (Cros And Cdmos)
    • Cros & Cdmos
    • Cros And Cdmos
    • Pharmaceutical & Biotechnology Companies
    • Pharmaceutical And Biotechnology Companies

    By Application

    • Hematopoiesis
    • Immunology And Infectious Diseases
    • Neuroscience
    • Oncology
    • Other Applications
    • Toxicology

    JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC AND RESEARCH INSTITUTES2.22.32.42.52.72.933.26
    CROS & CDMOS3.73.94.34.75.25.76.36.99.9
    PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES8.18.59.21010.811.712.613.68.3
    TOTAL1414.615.817.318.820.321.923.78.4

    Target Audience

    • Japanese Pharmaceutical Companies : Need market intelligence to optimize preclinical research investments, benchmark R&D spending against competitors, and identify opportunities for advanced animal model adoption in drug development pipelines.
    • Biotech Research Institutions : Require detailed market data to secure funding, justify equipment investments in humanized model facilities, and demonstrate alignment with growing industry demand for sophisticated preclinical testing.
    • Contract Research Organizations (CROs) : Seek Japan-specific market insights to expand service offerings, identify client demand patterns, and develop competitive positioning in the growing preclinical research outsourcing segment.
    • Animal Model Suppliers : Need market forecasts and growth projections to plan production capacity, develop Japan-focused sales strategies, and identify emerging opportunities in the humanized model segment.
    • Investment and Strategy Consultants : Require validated market data for Japan to advise clients on market entry, M&A opportunities, and strategic positioning in Asia Pacific's fastest-growing preclinical research markets.

    Key Companies in the Japan Humanized Mouse and Rat Model Market

    CompanyHQOwnershipStrongest segments
    CHARLES RIVER LABORATORIESUnited StatesPublic CompanyResearch Models and Services,Discovery and Safety Assessment,Manufacturing Solutions,
    THE JACKSON LABORATORYUnited StatesFoundation/Charitable InstitutionMouse breeding and colony management,Phenotyping, efficacy testing, and genetic research services,Genetic resources, software, and data,
    INOTIVUnited StatesPublic CompanyResearch Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software,
    GENOWAYFrancePublic CompanyCustom mouse models (KO/KI and humanized),Custom rat models,Engineered cell lines,
    JSR CORPORATIONJapanPrivate CompanyDigital Solutions (lithography, photoresists, CMP, display and packaging materials),Plastics / Synthetic Resins (ABS, AES, AS, ASA and related resins),Life Sciences (diagnostic and research reagents, bioprocess materials, drug discovery support),
    CHAMPIONS ONCOLOGY, INC.United StatesPublic CompanyTumorgraft / PDX-based translational oncology services,Personalized cancer care services,Lumin Bioinformatics and data-driven software,
    ONCODESIGN SERVICESFrancePublic CompanyPrecision oncology and immuno-oncology (OPM-101, OPM-102),Neurodegeneration (OPM-201, Parkinson’s),Radiotheranostic portfolio for digestive and pancreatic cancers,

    CHARLES RIVER LABORATORIES

    Charles River Laboratories is a public company founded in 1947 in the United States with 19,000 employees.

    THE JACKSON LABORATORY

    The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States with 2,100 employees.

    INOTIV

    Inotiv is a public company founded in 1974 in the United States with 1,996 employees.

    GENOWAY

    Genoway is a public company founded in 1999 in France with 157 employees.

    JSR CORPORATION

    JSR Corporation is a private company founded in 1948 in Japan with 7,997 employees.

    CHAMPIONS ONCOLOGY, INC.

    Champions Oncology, Inc. is a public company founded in 1985 in the United States with 214 employees.

    ONCODESIGN SERVICES

    Oncodesign Services is a public company founded in 1995 in France.

    Reasons to Buy this Report

    • Japan-Specific Market Sizing : Access precise valuation data for Japan's humanized mouse and rat model market with verified 2025 baseline (USD 12.9M) and 2030 forecasts, enabling accurate budget allocation and investment planning.
    • Competitive Landscape Intelligence : Understand Japan's unique market dynamics, local player strategies, and competitive positioning within the Asia Pacific region to identify partnership and expansion opportunities.
    • Growth Rate Benchmarking : Leverage Japan's 8.8% CAGR data to benchmark performance against global 8.2% growth, identifying Japan as an outperforming market for strategic resource allocation.
    • Regulatory and Market Insights : Gain Japan-specific insights on regulatory requirements, pharmaceutical sector trends, and research institution demands driving humanized model adoption in the country.
    • Strategic Market Entry Planning : Develop targeted go-to-market strategies for Japan with localized data on pharmaceutical investments, biotech growth, and preclinical research infrastructure development.

    Frequently asked questions

    What is the current market size of humanized mouse and rat models in Japan?

    Japan's humanized mouse and rat model market is valued at USD 12.9 million in 2025 and is expected to grow to USD 19.7 million by 2030.

    What is the projected growth rate for Japan's humanized mouse and rat model market?

    Japan's market is projected to grow at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2030.

    What factors are driving growth in Japan's humanized animal model market?

    Key drivers include increased R&D investment by pharmaceutical companies, regulatory support for alternative testing methods, Japan's aging population, and rising demand for personalized medicine research.

    Which therapeutic areas are driving demand for humanized models in Japan?

    Oncology, immunology, and infectious disease research are the primary therapeutic segments driving adoption of humanized mouse and rat models in Japan.

    How does Japan's market compare to the global humanized mouse and rat model market?

    Japan's market is growing at 8.8% CAGR, slightly outpacing the global CAGR of 8.2%, reflecting strong regional demand and investment in preclinical research infrastructure.

    RESEARCH METHODOLOGY

    The research study used secondary sources, directories, and databases to identify and collect valuable information to analyze the global humanized mouse and rat model market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size was estimated through secondary research (top-down and bottom-up), followed by data triangulation with inputs from industry experts to determine the final market size.

    Secondary Research

    Secondary research was used to identify and collect information for the technical, market-oriented, and commercial study of the humanized mouse and rat model market. The secondary sources used for this study include the American Association for Cancer Research (AACR), American Association for Laboratory Animal Science (AALAS), European Society for Medical Oncology (ESMO), European Association for Cancer Research (EACR), Humanized Mouse Resource (HMR), National Center for Biotechnology Information (NCBI), and Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

    Academic Journals and Company Websites; corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations were also used to obtain major information about key market players and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analyzed to determine the market size of the global humanized mouse and rat model market, which was further validated through primary research.

    Primary Research

    Primary research was conducted after acquiring basic knowledge about the global humanized mouse and rat model market through secondary research. A series of primary interviews were conducted with market experts from the demand side, including professionals from the pharmaceutical and biopharmaceutical industries and academic institutions. Additionally, interviews were held with individuals from the supply side, such as C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners. The primary interviews were conducted across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 80% and 20% of the primary interviews were conducted with supply-side and demand-side participants. This data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The breakdown of the primary respondents is given below.

    Humanized Mouse and Rat Model Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Top-down and bottom-up approaches were used to estimate and validate the total size of the humanized mouse and rat model market. These methods were also used extensively to estimate the size of various subsegments in the market.

    Humanized Mouse and Rat Model Market

    Data Triangulation

    After determining the market size from the above estimation process, the total market was divided into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from the demand and supply sides.

    Market Definition

    A humanized mouse and rat model is an immunodeficient organism genetically engineered to study immune responses to drugs or identify potential disease targets. These models are widely used to study human diseases and genes. Researchers in both academia and industry, along with clinicians, extensively use humanized mouse and rat models in their research applications. Humanized mouse and rat models are beneficial tools for immuno-oncology and infectious disease research. They have improved the ability to predict human responses to new therapeutics in clinical development.

    Stakeholders

    • Research and consulting firms
    • Biopharmaceutical manufacturers
    • Pharmaceutical manufacturers
    • Mouse model and service companies
    • Government and private research institutes
    • Manufacturers and suppliers of animal care products
    • Clinical research organizations (CROs)
    • Academic and research institutes
    • Venture capitalists
    • Laboratory animal care associations
    • Public and private animal health agencies

    Report Objectives

     

    To define, describe, and forecast the humanized mouse and rat model market by type, application, end user, and region

    To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)

    • To analyze the micromarkets1 concerning individual growth trends, prospects, and contributions to the overall humanized mouse and rat model market
    • To assess the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments for North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

     

    Get the Full Humanized Mouse and Rat Model Market Report

    Full forecast, segment splits, and company analysis for all Humanized Mouse and Rat Model Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status